METTL14 and ovarian cancer: In the study, METTL14 was lowly expressed in ovarian cancer samples and highly expressed in patients of Stage 1/2 subgroup and correlated with OC prognosis; thus, it is clear that the same M6A regulator also exerted different effects in different tumors.